Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
First Claim
Patent Images
1. A pharmaceutical composition deliverable from a metered dose inhaler, comprising:
- a suspension medium comprising a pharmaceutically acceptable propellant;
a plurality of active agent particles comprising a long-acting muscarinic antagonist (LAMA) active agent or a long-acting β
2 adrenergic receptor agonist (LABA) active agent; and
a plurality of respirable suspending particles, wherein the respirable suspending particles are formed separately from and are different particles than the active agent particles and are formed of a dry particulate phospholipid material that is substantially insoluble in the suspension medium;
and wherein the ratio of the total mass of the respirable suspending particles to the total mass of the active agent particles is from greater than 1;
1 up to 200;
1.
0 Assignments
0 Petitions
Accused Products
Abstract
Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting β2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
-
Citations
41 Claims
-
1. A pharmaceutical composition deliverable from a metered dose inhaler, comprising:
-
a suspension medium comprising a pharmaceutically acceptable propellant; a plurality of active agent particles comprising a long-acting muscarinic antagonist (LAMA) active agent or a long-acting β
2 adrenergic receptor agonist (LABA) active agent; anda plurality of respirable suspending particles, wherein the respirable suspending particles are formed separately from and are different particles than the active agent particles and are formed of a dry particulate phospholipid material that is substantially insoluble in the suspension medium; and wherein the ratio of the total mass of the respirable suspending particles to the total mass of the active agent particles is from greater than 1;
1 up to 200;
1. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
-
26. A method for treating a pulmonary disease or disorder in a patient, wherein the pulmonary disease or disorder is selected from at least one of the group consisting of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, and pulmonary inflammation or obstruction resulting from cystic fibrosis, the method comprising administering a therapeutically effective amount of a pharmaceutical composition from a metered dose inhaler, the pharmaceutical composition comprising:
-
a suspension medium comprising a pharmaceutically acceptable propellant; a plurality of active agent particles comprising a LAMA active agent or a LABA active agent; and a plurality of respirable suspending particles, wherein the respirable suspending particles are formed separately from and are different particles than the active agent particles and are formed of a dry particulate phospholipid material that is substantially insoluble in the suspension medium; and wherein the ratio of the total mass of the respirable suspending particles to the total mass of the active agent particles is from greater than 1;
1 up to 200;
1. - View Dependent Claims (27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)
-
Specification